Belgium's Genae has expanded its European footprint, cutting the ribbon on a Swiss office with its eye on a bigger share of the market for medical device development.
The CRO's Zurich outpost will serve as its second European hub, and the addition will help the growing company increase its client base among device and biologics developers, CEO Bart Segers said.
"The Swiss offices reflect the growing demand of our strategic partners to provide local presence and tailored support," Segers said. "With local anchoring, we aim at accelerating high-quality and cost-contained recruitment and execution of our medical device trials in Switzerland and other European countries."
Genae has been steadily raising its profile since opening a U.S. branch in 2011, and the company hopes an October partnership with Yale University will further expand visibility. Genae teamed up with the Yale Cardiovascular Research Group, the school's in-house clinical service provider, to share and subcontract monitoring, regulatory, safety, core laboratory, data management and statistical analysis services for medical device clients.
The CRO, founded in 2005, handles clinical trial management, data management, statistical analysis, safety, regulatory, core lab and medical writing services.
- read the announcement